Daraxonrasib

What is daraxonrasib?

Daraxonrasib is a medication to treat metastatic pancreatic adenocarcinoma, the most common type of pancreatic cancer. It is intended for certain patients who have received at least one previous treatment, or who cannot receive other cancer medicines.

Daraxonrasib is a targeted cancer therapy, which means it targets the biology of cancer cells. It is also referred to as ‘RMC-6236’ and has the brand name ‘Rasonque’.

Pancreatic cancer remains difficult to treat, and daraxonrasib represents a significant development. It was approved for use by the FDA in August 2026 in certain adult patients with metastatic pancreatic cancer. Research is ongoing into its possible use as a treatment for other cancers.

How does daraxonrasib work?

Daraxonrasib is an anticancer medication that belongs to a group of medicines called RAS inhibitors. It is a targeted therapy designed to interfere with RAS proteins, which play an important role in regulating cell growth and survival.

RAS proteins act as molecular switches that control how a cell grows, divides and survives. If the RAS protein is mutated, the switch can become stuck in the ‘on’ position, and the cells grow and multiply in an uncontrolled way, forming tumors. KRAS is a gene that produces the K-RAS protein, one member of the RAS protein family. Changes in KRAS are particularly common in pancreatic cancer

As a RAS inhibitor, daraxonrasib works by targeting active forms of RAS proteins, including K-RAS, and disrupts the signals involved in cell growth and survival. By interfering with these signals, daraxonrasib may help slow cancer growth. However, its effects vary, and it does not work for every patient

Pancreatic cancer has historically been hard to treat. By targeting RAS, a key cancer-driving pathway that has been challenging to target for many years, daraxonrasib represents a significant development.

Who may be eligible for daraxonrasib?

In the US, daraxonrasib is approved for certain adults with metastatic pancreatic adenocarcinoma, who have received at least one previous round of chemotherapy or who are not candidates for combination chemotherapy. It is not suitable for everyone with pancreatic cancer.

Eligibility depends on other factors, including individual diagnosis, stage of disease, previous treatment and overall health.

Is daraxonrasib a type of chemotherapy?

No, daraxonrasib is a targeted therapy rather than conventional chemotherapy, although both are types of anticancer treatment.

Conventional chemotherapy generally works by damaging cells or interfering with processes involved in cell division. Targeted therapies like daraxonrasib interfere with specific proteins or signalling pathways that help cancer cells grow and survive.

Chemotherapy can affect cells throughout the body and cause widespread side effects. Targeted therapies interfere with specific proteins or signaling pathways involved in cancer growth. Although they are designed to target particular biological processes, they can also affect healthy tissues and cause significant side effects.

Standard chemotherapy is given in many ways, including via an infusion, which can take several hours with multiple visits often needed. Daraxonrasib is a pill, taken once a day at home, which may offer practical advantages over chemotherapy.

What are the side effects of daraxonrasib?

The most common side effect of daraxonrasib is a rash Other sideeffects may include diarrhea, inflammation or sores in the mouth, nausea, vomiting and fatigue.

Other side effects may occur, and some can be serious. Patients taking daraxonrasib will be monitored closely by their care team.

What are the benefits of daraxonrasib?

Clinical trials suggest daraxonrasib may help certain people with metastatic pancreatic cancer live longer and delay the cancer from progressing, compared to chemotherapy.

As daraxonrasib is a once-a-day pill that can be taken at home, it may offer practical advantages over standard chemotherapy infusions for eligible patients.

Daraxonrasib is not suitable for all patients with pancreatic cancer. The benefits and risks of any medication should be discussed with a cancer specialist, who can help you decide whether it is appropriate, based on individual diagnosis, previous treatments and overall health.